Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$74.43 - $92.22 $12.9 Million - $15.9 Million
172,949 New
172,949 $14.2 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $904,745 - $1.07 Million
-11,012 Reduced 6.6%
155,849 $13.2 Million
Q2 2022

Aug 15, 2022

SELL
$71.48 - $86.85 $11.7 Million - $14.2 Million
-163,401 Reduced 49.48%
166,861 $13.8 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $12.9 Million - $16.1 Million
-173,357 Reduced 34.42%
330,262 $25.5 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $7.11 Million - $9.07 Million
-99,181 Reduced 16.45%
503,619 $44.5 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $11.4 Million - $13 Million
152,000 Added 33.72%
602,800 $46.6 Million
Q2 2021

Aug 16, 2021

BUY
$75.51 - $84.79 $9.29 Million - $10.4 Million
123,000 Added 37.52%
450,800 $37.6 Million
Q1 2021

May 17, 2021

BUY
$74.73 - $90.69 $24.5 Million - $29.7 Million
327,800 New
327,800 $24.8 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Melqart Asset Management (Uk) LTD Portfolio

Follow Melqart Asset Management (Uk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.